Janux Therapeutics

(NASDAQ) JANX

Current Price$14.35

Market Cap$884.49M

Since IPO (2021)-42%

5 YearN/A

1 Year-43%

1 Month-3%

Janux Therapeutics Financials at a Glance

Market Cap

$884.49M

Revenue (TTM)

$21.61M

Net Income (TTM)

$114.48M

EPS (TTM)

$-1.83

P/E Ratio

-7.93

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$14.35

Volume

235,123.291

Open

$14.44

Price

$14.35

Volume

235,123.291

Open

$14.44

Previous Close

$14.54

Daily Range

$13.90 - $14.65

52-Week Range

$12.12 - $35.34

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$14.35

Volume

235,123.291

Open

$14.44

Previous Close

$14.54

Daily Range

$13.90 - $14.65

52-Week Range

$12.12 - $35.34

JANX News

JANX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Janux Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

109

CEO

David Campbell, PhD

Website

www.januxrx.com

Headquarters

San Diego, CA 92037, US

JANX Financials

Key Financial Metrics (TTM)

Gross Margin

39%

Operating Margin

-7%

Net Income Margin

-5%

Return on Equity

-11%

Return on Capital

-16%

Return on Assets

-11%

Earnings Yield

-12.61%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$884.49M

Shares Outstanding

60.83M

Volume

235.12K

Avg. Volume

1.03M

Financials (TTM)

Gross Profit

$7.97M

Operating Income

$157.67M

EBITDA

$111.60M

Operating Cash Flow

$82.23M

Capital Expenditure

$1.04M

Free Cash Flow

$83.28M

Cash & ST Invst.

$966.57M

Total Debt

$22.14M

Janux Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$3.73M

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$884.49M

N/A

Market Cap/Employee

$9.72M

N/A

Employees

N/A

Net Income

$24.36M

-3.6%

EBITDA

$34.21M

+0.5%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$934.82M

-5.7%

Accounts Receivable

$35.00M

+526.7%

Inventory

$0.00

N/A

Long Term Debt

$19.10M

-8.2%

Short Term Debt

$2.47M

+36.5%

Return on Assets

-11.13%

N/A

Return on Invested Capital

-16.20%

N/A

Free Cash Flow

$12.61M

+27.5%

Operating Cash Flow

$12.34M

+27.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

BHVNBiohaven Ltd.

BHVNBiohaven Ltd.$9.76+0.26%

MAZEMaze Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.$25.60+0.51%

ABCLAbCellera Biologics Inc.

ABCLAbCellera Biologics Inc.$5.09+5.60%

NUVBNuvation Bio Inc.

NUVBNuvation Bio Inc.$4.87+1.14%

ZYMEZymeworks Inc.

ZYMEZymeworks Inc.$24.14-9.27%

HRMYHarmony Biosciences Holdings, Inc.

HRMYHarmony Biosciences Holdings, Inc.$31.75+1.05%

IMNMImmunome, Inc.

IMNMImmunome, Inc.$22.53+1.53%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$15.37+0.06%

RXTRackspace Technology

RXTRackspace Technology$4.93+0.40%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$74.50+0.04%

OPENOpendoor Technologies

OPENOpendoor Technologies$4.96-0.07%

FLNCFluence Energy

FLNCFluence Energy$24.81+0.31%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$43.74-0.04%

EOSEEos Energy Enterprises

EOSEEos Energy Enterprises$7.50+0.18%

Questions About JANX

What is the current price of Janux Therapeutics?

Janux Therapeutics is trading at $14.37 per share.

What is the 52-week range for Janux Therapeutics?

Over the past 52 weeks, Janux Therapeutics has traded between $12.12 and $35.34.

How much debt does Janux Therapeutics have?

As of the most recent reporting period, Janux Therapeutics reported total debt of $21.57M.

How much cash does Janux Therapeutics have on hand?

Janux Therapeutics reported $51.83M in cash and cash equivalents in its most recent financial results.

What is Janux Therapeutics’s dividend yield?

Janux Therapeutics does not currently have a dividend yield.

Janux Therapeutics

Janux Therapeutics Financials at a Glance

JANX News

Options Exercise: Janux Executive Sells 16,665 Shares for $501,000

Janux (JANX) R&D Soars Revenue Misses

Why Janux Therapeutics Crushed the Market Today

Why Janux Therapeutics Stock Is Crushing It This Week

Why Janux Therapeutics Stock Soared as the Market Sagged Today

After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?

Why Janux Therapeutics Shares Rose 33.1% This Week

JANX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Janux Therapeutics

JANX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Janux Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About JANX

What is the current price of Janux Therapeutics?

What is the 52-week range for Janux Therapeutics?

How much debt does Janux Therapeutics have?

How much cash does Janux Therapeutics have on hand?

What is Janux Therapeutics’s dividend yield?

Premium Investing Services